BioMarin achondroplasia treatment granted orphan designation by EMA Orphan designation granted by the European Commission to BioMarin Europe for modified recombinant human C-type natriuretic peptide for the treatment of achondroplasia on Jan. 24, according to posting to European Medicines Agency site. Reference Link
BioMarin upgraded to Buy from Neutral at Goldman Goldman upgraded BioMarin to Buy based on increased confidence in BMN-111 for achondroplasia with expected proof-of-concept data in Q2 2015. The firm now sees a greater than 50% probability of success and peak sales of $900M. Price target raised to $104 from $78.